Abstract
Pulmonary fibrosis is a fatal chronic progressive respiratory disease, characterized by continuous scarring of the lung parenchyma, leading to respiratory failure and death. The incidence of PF has increased over time. There are drugs, yet, there are some limitations. Hence, it is of importance to find new therapies and new drugs to replace the treatment of pulmonary fibrosis. In recent years, there have been a great number of research reports on the treatment of traditional Chinese medicine polysaccharides in various system fields. Among them, the treatment of PF has also gained extensive attention. This review summarized the source of polysaccharides, the drug activity of traditional Chinese medicine, and the protective effects on targets of Pulmonary fibrosis. We hope it can inspire researchers to design and develop polysaccharides, serving as a reference for potential clinical therapeutic drugs.
Highlights
Pulmonary fibrosis (PF) is a large category of pulmonary diseases refers to the proliferation of fibroblasts and the accumulation of a large amount of extracellular matrix (ECM), accompanied by inflammatory damage, and tissue structure destruction, which can cause breathing difficulties, cough, hypoxemia, and hinder gas exchange, eventually leading to respiratory failure (Phan et al, 2021)
This review summarized the source of polysaccharides, the drug activity of traditional Chinese medicine, and the protective effects on targets of Pulmonary fibrosis
These polysaccharides can significantly improve the abnormal recruitment and apoptosis of various cells in the lung tissue induced by the TGF-β signaling pathway, regulate the imbalance of the body caused by lung inflammation, and can control lung tissue damage through oxidative stress, confirming these polysaccharides can stabilize PF lung function and prevent further damage
Summary
Pulmonary fibrosis (PF) is a large category of pulmonary diseases refers to the proliferation of fibroblasts and the accumulation of a large amount of extracellular matrix (ECM), accompanied by inflammatory damage, and tissue structure destruction, which can cause breathing difficulties, cough, hypoxemia, and hinder gas exchange, eventually leading to respiratory failure (Phan et al, 2021). Improve the status of PF by improving the antioxidant capacity of the lung, reducing inflammatory cell infiltration and collagen deposition, improving the content of CAT and SOD, increasing the levels of GSH, GSH-Px, and reducing the content of MDA and HYP in lung tissue Inhibit MMP-9 and TIMP-2 in lung tissue of BLM pulmonary fibrosis mice, reduce HYP content and COL level, and inhibit the expression of TNF-a, NF-kB in lung tissue of pulmonary fibrosis YPF-p treats PF by downregulating the expression of TGF-β1 mRNA and improving the excessive aggregation of fibroblasts induced by TGF-β1, which reduces the expression of HYP, COL and a-SMA in lung tissue (Pan et al, 2012; Chen et al, 2016; Wang et al, 2017b; Sohretoglu and Huang, 2018; Zeng et al, 2018; Zeng et al, 2019)
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
